Eli Lilly Raises 2026 Revenue Guidance to $91B-$92B Driven by GLP-1 Demand
Question
Eli Lilly Raises 2026 Revenue Guidance to $91B-$92B Driven by GLP-1 Demand
Direct answer
A $5.5B upward revision in 2026 top-line guidance supports LLY's 47x forward P/E multiple against biopharma sector multiple compression. — bullish pressure on LLY via forward revenue guidance upgrade to $91B-$92B.
- Original publisher
- Market Ontology
- Evidence through
- 2026-11-08
- Published
- 2026-11-08
- Revision
- 1 · 2026-11-08
Cite as: Market Ontology, “Eli Lilly Raises 2026 Revenue Guidance to $91B-$92B Driven by GLP-1 Demand”, revision 1, evidence through 2026-11-08. https://marketontology.com/catalysts/2026-11-08/eli-lilly-raises-2026-revenue-guidance-to-91b-92b-driven-by-glp-1-demand-b86abc
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| LLY | ▲Bull | 1–4 weeks | forward revenue guidance upgrade to $91B-$92B | 87 |
Eli Lilly Raises 2026 Revenue Guidance to $91B-$92B Driven by GLP-1 Demand
A $5.5B upward revision in 2026 top-line guidance supports LLY's 47x forward P/E multiple against biopharma sector multiple compression. — bullish pressure on LLY via forward revenue guidance upgrade to $91B-$92B.
Source reports Eli Lilly raised 2026 revenue guidance to $91-92 billion from $85-87 billion.
- SourceSource reports Eli Lilly raised 2026 revenue guidance to $91-92 billion from $85-87 billion.
- TransmissionA $5.5B upward revision in 2026 top-line guidance supports LLY's 47x forward P/E multiple against biopharma sector multiple compression.
- SummaryEli Lilly raised its 2026 revenue outlook by $5.5 billion to $91 billion-$92 billion. Growth continues to stem from robust prescription volumes for Mounjaro and Zepbound. The equity trades at 47x P/E following a 57% run-up.
- LLYDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- LLY closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- LLY price vs. pre-event level
- LLY volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-11-08Eli Lilly raised 2026 revenue guidance by $5.5B to $91B-$92B on GLP-1 salesLLY
- 2026-11-08Novo Nordisk jumped 6% after oral weight-loss pill generated $810M in Q3LLY NVO
- 2026-11-08Eli Lilly Lifts Revenue Forecast by $5.5B as Novo Oral GLP-1 Sales RiseLLY NVO
- 2026-11-08Novo Nordisk and Lilly keep GLP-1 growth in focusIBB LLY NVO
- 2026-11-08Novo Nordisk and Lilly keep GLP-1 growth in focusLLY NVO
- 2026-11-08Eli Lilly Lifts Revenue Forecast by $5.5B as Novo Oral GLP-1 Sales RiseLLY NVO
- 2026-11-08Novo Nordisk raises full-year guidance after strong Q3LLY NVO
- 2026-11-08Eli Lilly raised 2026 revenue guidance by $5.5B to $91B-$92B on GLP-1 salesLLY NVO
Find trades for this development
Screen tradable expressions of this catalyst against your horizon and constraints. Nothing is submitted without your review.
First 10 runs free
See today's live cards
Public pages are published 24 hours after the product shows them. The product shows every catalyst, event and causal reading as it happens, mapped to your holdings.